{"schema_version":"secwatch.filing_event.v1","accession":"0001628908-24-000015","form_type":"8-K","ticker":"EVH","cik":"0001628908","company_name":"Evolent Health, Inc.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.863791+00:00","generated_at":"2026-06-05T19:27:29.499356+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evolent Health Q4 revenue $556M, FY revenue $1.96B (+45%); net loss ($142M), adj EBITDA $194.7M (+84%)","bullets":["Full year 2023 revenue of $1,963.9M, up 45% YoY; net loss of $(142.3)M (net loss margin -7.2%).","Adjusted EBITDA of $194.7M, up 84% YoY; cash flow from operations of $142.6M.","Q4 2023 revenue $556.1M, net loss $(41.4)M, adjusted EBITDA $48.1M (8.6% margin).","Initial 2024 outlook: revenue growth ~25% at midpoint, consistent with long-term targets.","Announced four new revenue agreements, including first comprehensive oncology bundle and first Performance Suite for advanced imaging."],"urls":{"canonical":"https://secwatch.observer/filing/0001628908-24-000015","json":"https://secwatch.observer/filing/0001628908-24-000015.json","markdown":"https://secwatch.observer/filing/0001628908-24-000015.md","text":"https://secwatch.observer/filing/0001628908-24-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628908/000162890824000015/0001628908-24-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628908/000162890824000015/evh-20240222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T19:27:29.499356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"10e4c693423423727fe3d60dded6f54a7e925a04","claim":"Evolent Health, Inc. updated its 2024 guidance (initiated).","evidence_excerpt":"Provides initial outlook for 2024 in line with long-term targets","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890824000015/0001628908-24-000015-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2024"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"f523e17ef72150af41719485e8fdd4fcf1c67162","claim":"Evolent Health, Inc. reported the quarter and year ended December 31, 2023 results: revenue $556,055 thousand, $1,963,896 thousand, net income ($41,395) thousand, ($142,260) thousand.","evidence_excerpt":"Evolent Announces Fourth Quarter and Full Year 2023 Results • Full year revenue of $1,963.9 million, 45% growth over 2022 • Net loss attributable to common shareholders of Evolent Health, Inc. of $(142.3) million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890824000015/0001628908-24-000015-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$556,055 thousand, $1,963,896 thousand"},{"label":"Net income","value":"($41,395) thousand, ($142,260) thousand"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}